Ömer Damar, Mahmut Yaman
Background: Early identification of patients at risk of severe acute pancreatitis (AP) remains a clinical priority. We evaluated whether the admission Systemic Immune-Inflammation Index (SII, ×109/L) adds prognostic value to the BISAP score, alone and in combination. SII integrates neutrophil, lymphocyte, and platelet counts from the routine complete blood count. Methods: In this retrospective single-center cohort, 523 adults with AP (January 2020-December 2025) were classified by the Revised Atlanta Classification. Admission SII and BISAP were related to severe AP, intensive care unit (ICU) admission, and in-hospital mortality using logistic regression, ROC analysis with DeLong comparison, 1000-sample bootstrap validation, and decision curve analysis. Results: Severe AP occurred in 48 patients (9.2%), ICU admission in 61 (11.7%), and death in 26 (5.0%). Admission SII was markedly higher in severe than non-severe disease (4085 vs. 1499; p < 0.001). Both SII and BISAP independently predicted all three outcomes after mutual adjustment (severe AP: SII odds ratio 2.12 and BISAP odds ratio 4.92 per standard deviation). For severe AP, the combined BISAP + SII model outperformed either marker (AUC 0.954 vs. 0.911 and 0.917), as it did for mortality (0.957); for ICU admission SII was the strongest single marker (0.869) and the combined model did not significantly improve discrimination compared with SII alone (DeLong p = 0.287). Internal validation showed adequate calibration with modest optimism and suggested potential net clinical benefit across the evaluated threshold ranges, pending external validation. Conclusions: Combining the admission SII with the BISAP score provides incremental prognostic information beyond BISAP alone for the early risk stratification of severe acute pancreatitis and in-hospital mortality using data already available at presentation. External, prospective validation is warranted before routine adoption.